Radial

Based in the US, Radial provides innovative mental health treatments, focusing on advanced therapies for conditions such as depression, anxiety, PTSD, and ADHD, aimed at delivering effective care for diverse patient needs. Founded in 2023 and headquartered in New York, US, Radial specializes in advanced mental health treatments. The company has successfully completed 1 deal, raising USD 50. 00 mn in Series A funding on December 9, 2025, led by General Catalyst Partners with participation from multiple investors including BoxGroup and Scrub Capital.

The founder of Radial has not been detailed, nor are there references to subsidiaries or parent companies. Radial specializes in advanced mental health treatments, providing a comprehensive array of innovative solutions designed to address various mental health conditions such as depression, anxiety, PTSD, and ADHD. The company employs a multi-faceted approach that includes treatments like accelerated Transcranial Magnetic Stimulation (TMS), FDA-approved Spravato® (esketamine) nasal spray, PRISM neurofeedback, and vagus nerve neurostimulation. These therapies aim to deliver rapid relief and target specific brain regions involved in mood regulation, offering alternatives to traditional antidepressants and talk therapy.

Radial's client base comprises individuals seeking effective mental health solutions, including those who have not responded positively to conventional treatments. Geographically, Radial operates a network of practices across the United States, enhancing accessibility to its advanced care for a diverse range of patients nationwide. Radial generates revenue through its direct-to-consumer model, which centers on providing specialized mental health treatment services. The company operates on a fee-for-service structure, where clients pay for individual treatment sessions or packages that may include initial consultations, ongoing therapy, and follow-up care.

Services such as TMS and Spravato® treatment may be covered by insurance, thereby facilitating transaction processes between Radial and its clients. This structure enables patients to engage with a range of treatment options, tailored to their specific needs, while also allowing Radial to maintain a steady stream of revenue from both insured and self-paying customers. The company continues to expand its offerings, ensuring that its innovative treatments remain accessible to those in need. In December 2025, Radial raised USD 50 mn in Series A funding, led by General Catalyst Partners, to enhance access to mental health treatments.

The funding will be used to build clinical infrastructure, reimbursement systems, and AI-based decision support tools. The company plans to expand its services into new markets, aiming for broader geographic reach to improve accessibility for patients in need of mental health care.